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BACKGROUND: The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic
neuroendocrine tumours (PanNETs) treated with sunitinib.
METHOD: A multicentre, prospective study was conducted in 10 Spanish centres. Computed tomographies, at least every
6 months, were centrally evaluated until tumour progression.
RESULTS: One hundred and seven patients were included. Median progression-free survival (PFS) by RECIST and Choi were 11.42
(95% confidence interval [CI], 9.7–15.9) and 15.8 months (95% CI, 13.9–25.7). PFS by Choi (Kendall’s τ= 0.72) exhibited greater
correlation with overall survival (OS) than PFS by RECIST (Kendall’s τ= 0.43). RECIST incorrectly estimated prognosis in 49.6%. Partial
response rate increased from 12.8% to 47.4% with Choi criteria. Twenty-four percent of patients with progressive disease according
to Choi had stable disease as per RECIST, overestimating treatment effect. Choi criteria predicted PFS/OS. Changes in attenuation
occurred early and accounted for 21% of the variations in tumour volume. Attenuation and tumour growth rate (TGR) were
associated with improved survival.
CONCLUSION: Choi criteria were able to capture sunitinib’s activity in a clinically significant manner better than RECIST; their
implementation in standard clinical practice shall be strongly considered in PanNET patients treated with this drug.
British Journal of Cancer (2019) 121:537–544; https://doi.org/10.1038/s41416-019-0558-7
BACKGROUND
Pancreatic neuroendocrine tumours (PanNETs) are a heteroge-
neous, typically slow-growing group of neoplasms.1 One of their
biological hallmarks is their rich microvascular density that
originates in the dense vascular network of the pancreatic islet.
This structure is sustained by a host of proangiogenic molecules,
such as vascular endothelial growth factor receptors (VEGFR),
platelet-derived growth factor receptor (PDGFR) and others.2,3 As a
result, PanNETs appear as hypervascular masses on computed
tomographies (CT), with avid contrast enhancement in the arterial
phase.4 The intensity of radiological enhancement correlates with
the microvascular density.5
In the phase III randomised trial SUN1111 conducted in advanced,
progressive, grade 1/2 PanNET, the use of the multikinase inhibitor
(MKI) sunitinib, which targets VEGFR 1, 2, and 3, as well as PDGFR,
improved progression-free survival (PFS).6,7 Other antiangiogenic
drugs that inhibit the VEGF/VEGFR pathway, such as lenvatinib,
pazopanib, cabozantinib, surufatinib or famitinib, are being actively
evaluated in PanNETs.8 These molecules foster the appearance of
altered, meandering tumour vessels that are susceptible to leaks
associated with areas of necrosis within the tumour.9 The
tomographic correlate includes cystic degeneration or intratumoural
hypodensity, common radiological findings that are considered
evidence of in vivo activity of the antiangiogenic agent.10 In
contrast, clinical trials with these drugs in PanNETs usually reveal low
rates of tumour shrinkage.6,11
Response Evaluation Criteria In Solid Tumors (RECIST) were
developed to quantify efficacy of cytotoxic chemotherapy
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according to the degree of tumour regression.12 Despite their
wide acceptance and reproducibility, their limitations are becom-
ing better known when evaluating the antiproliferative and
antiangiogenic effects of targeted molecular agents,13,14 especially
in slow-growing tumours such as PanNETs.15–17 This translates as
an underestimation of treatment effect in clinical trials and the
inappropriate discontinuation of effective therapies in the case
of tumours that maintain hypo-attenuation as a correlate
for effective biological activity, despite a discrete increase in
diameters.10,16,18
In response to these challenges, Choi et al. were the first to
propose that the combined variation in tumour density and size,
with lower thresholds than the ones used by RECIST, was an
appropriate method by which to monitor response to targeted
therapies.19–22 Comparative data suggest improved performance
of Choi versus RECIST criteria in a number of solid tumours
including neuroendocrine tumours;10,18,16 however, further eva-
luations are needed to validate this promising preliminary results
prior to recommending their widespread use for PanNETs in
clinical practice.
Against this backdrop, the CRIPNET_GETNE1504-study
(NCT02841865) seeks to compare the usefulness of Choi versus
RECIST criteria in well-differentiated, advanced PanNETs and to
discern which criterion best captures sunitinib’s activity in this
population.
METHODS
Study design and patients
CRIPNET_GETNE1504 is a multicentre study classified by the
Spanish Agency of Medicines and Medical Devices (AEMPS, for its
acronym in Spanish) as a post-authorisation trial of prospective
follow-up. It was conducted at 10 sites of the Spanish Group of
Neuroendocrine and Endocrine Tumors (GETNE, for its acronym in
Spanish) and recruited consecutive patients with advanced, well-
differentiated PanNETs treated with sunitinib between 2012–2017.
The study did not include any kind of intervention. The decision to
modify treatment was therefore based on the investigator’s
criterion, according to local standard radiological evaluation as per
RECIST. The study was approved by the Ethics Review Boards of
the participating centres and by the healthcare authorities of each
geographical region. All subjects gave their written informed
consent to participate in the study.
Eligibility criteria included: histological confirmation of PanNET,
Ki-67 index ≤ 20%, availability of serial image studies, with arterial
and portal phase, within the 4 weeks prior to initiating treatment
with sunitinib and at least every 6 months until progression or the
end of the study. Individuals were excluded if they received other
concurrent antiproliferative treatments, with the exception of
somatostatin analogues prescribed for their anti-secretory effect;
those with short exposure to sunitinib (fewer than two cycles) due
to causes other than demise or clinical decline, or with previous
use of other antiangiogenic agents. Cases with suboptimal or non-
standard CT assessment (e.g. insufficient enhancement with
contrast, insufficient body coverage), or the absence of measur-
able disease were likewise excluded.
Sunitinib was started at the standard dose, 37.5 mg/day, and
the criteria for dose reductions and delays were done as per the
summary of product characteristics and the clinical judgment of
the attending medical oncologist, expert in the management of
PanNETs.
Objectives
The main objective of the study was to assess the association of
RECIST v1.1 and Choi criteria on survival endpoints. Other aims
were to analyse whether PFS as per Choi is a better surrogate
endpoint for overall survival (OS) than PFS according to RECIST,
and to appraise the correlation with prognosis of attenuation
variation rate (AVR), tumour growth rate (TGR) and diameter
variation rate (DVR).
Measures (acquisition, imaging analysis and criteria of evaluation)
Patients underwent contrast-enhanced CT imaging of the chest,
abdomen and pelvis. The equipment used in these studies was CT
multidetector (64– or 128–detector row scanners). All studies had
to be performed with intravenous contrast according to each
centre’s standard protocol, including arterial and portal venous
phase imaging deemed optimal for accurate evaluation, with a
minimum of 5-mm reconstruction intervals. Images were inde-
pendently read by two radiologists, specialised in NETs, who were
blind to local results and to clinical data, and reached a consensus
regarding their evaluation of response. PFS was defined as the
time in months from initiation of treatment with sunitinib until
progression or death, censoring event-free subjects.
Choi and RECIST v1.1 criteria were analysed as per the usual
descriptions.12,23 The exact definitions followed to interpret the
images are displayed in Supplementary Table 1. In keeping with
RECIST v1.1, up to five target lesions were selected (maximum of
two per organ involved) calculating the sum of target lesions in
conformity with pre-established criteria.12 The Hounsfield unit
(HU) value was obtained using the mean attenuation of the pixels
of the region of interest within the contour of the target lesions in
arterial phase. The result was averaged to obtain a mean measure
of CT attenuation. Changes in size or attenuation were calculated
in absolute or relative terms against baseline values and the
previous CT. The AVR and DVR were calculated by dividing the
relative changes in density and size by the time since
commencement of sunitinib until evaluation of response. The
TGR was calculated according to the definition by Ferté.24 Tumour
size was defined as the baseline sum of target lesion diameters
(D0), while Dt is the same measure after time (t) has elapsed. Thus,
tumour growth (TG) was calculated using the formula: TG= 3 Log
(Dt/D0)/t. To express this magnitude in clinically relevant terms, TG
was expressed as a percentage of variation over 1 month, by
means of the transformation: TGR= 100 (exp(TG) −1).
Statistics
Cohen’s kappa was used as a measure of concordance between
Choi/RECIST criteria. Correlation between PFS & OS was quantified
by means of Kendall’s τ associated with Clayton’s copula models
for bivariate survival data.25 Wilcoxon signed rank test was used
for paired data to compare variations in size/attenuation between
consecutive radiological studies. A landmark estimation was made
for PFS at 24 months, after 6 months of follow-up. The landmark
method estimates the likelihood of survival after a set period of
time and is suitable for time-dependent variables, such as tumour
response.26,27 In this case, the landmark coincides approximately
with the date of the evaluations of response conducted in the
patients. The prognostic effect was appraised by Cox proportional
hazards regression, factoring in the time-dependent nature of the
evaluation of response. The Mantel–Byar test was used to
compare survival endpoints as per Choi or RECIST. This method
is a modification of the log-rank test that avoids bias in survival
analysis by tumour response.27 The analyses were executed with
the RStudio statistical software (RStudio, Inc., Boston, MA, USA),
including the landest, survival and rgl packages.28–30
RESULTS
Patients
One hundred and seven patients were recruited, 22 of whom were
excluded as they did not meet the quality requirements per
protocol for imaging studies, including the adequate predefined
frequency of procedures. The baseline characteristics of the 85
individuals included are presented in Table 1. Participants had a
median age of 59 years (range, 21–84) and 58% were male.
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PanNETs had a median Ki67% of 7 (range, 1–20) and in 62%,
metastases were limited to a single organ. Sixty-five percent
received sunitinib after a somatostatin analogue. Sunitinib was
maintained for a median of 52 weeks (range, 7–301), with dose
reductions reported in 36% of treated patients.
Evaluation of PFS by RECIST versus Choi
During the follow-up period, 73 progression events were detected
by RECIST and 64 by Choi criteria. The median PFS centrally
evaluated were 11.42 months (95% confidence interval [CI],
9.7–15.9) as defined by RECIST and 15.8 (95% CI, 13.9–25.7) as
per Choi criteria. PFS by Choi exhibited greater correlation with OS
(Kendall’s τ= 0.722, standard error [SE]= 0.046) than PFS by
RECIST (Kendall’s τ= 0.439, SE= 0.068) (see scatter plot of
bivariate survival copulas in Fig. 1a, b). Of note, investigator-
evaluated PFS was 14.5 months (95% CI, 11.8–18.0).
Evaluation of tumour response in the first six months
Of the 85 subjects with a valid baseline CT, 78 had a CT at
6 months. At this time point, agreement between RECIST and Choi
was weak (Cohen’s Kappa for 2 Raters, 0.392, p < 0.001). The
transition diagram for both methods is shown in Fig. 2. According
to RECIST, 12.8% attained a partial response (PR), 56.4% stable
disease (SD) and 30.7% progressive disease (PD). When Choi
criteria were applied, the main change was the increase in the
percentage of PR, up to 47.4%, at the expense of decreasing the
rate of SD to 15.3%, and of a slight increment in the percentage of
PD (37.1%).
Supplementary Table 2 summarises the association of the 6-
month tumour response assessment with survival endpoints.
Landmark survival curve estimates are reported in Fig. 3. Choi
criteria are seen to be significantly effective at predicting both PFS
and OS (Mantel–Byar tests, p ≤ 0.001, in both cases). Evaluation by
RECIST was associated significantly with OS. On the other hand, no
statistical evidence was found to favour the association between
tumour response per RECIST and PFS (Mantel–Byar test, p= 0.4). It
must be remembered that, by definition, this analysis only
contemplated two categories (PR and SD), as the RECIST-based
PD endpoint coincided with the date of the CT in remaining cases
that were found to be in progression (infinite, non-calculable
hazard ratio [HR]). In contrast, the Choi-based PD (n= 29)
identified a group at greater risk for progression as per RECIST
(HR 2.55, 95% CI, 1.09–5.96) and for death (HR 2.44, 95% CI,
0.99–5.97). Tumour progression, by both RECIST and Choi criteria,
increased the risk of death with an equivalent magnitude of effect
in both cases. However, had only morphological criteria been
applied, 7/29 patients with PD by Choi (24%) would have been
classified as SD by RECIST. This would have overestimated these
subjects’ prognosis, given that the 24-month OS rate (landmark)
was 81.7% (95% CI, 69.6–91.1%) for SD as per RECIST, versus 50.1%
(95% CI, 33.7–67.5%) for PD according to Choi criteria (see
Supplementary Table 2). Furthermore, the median PFS in these
seven subjects was 13.4 months when the endpoint was defined
by RECIST versus 5.5 months as per Choi, which potentially entails
7.9 months of missed opportunity to change treatment
Likewise, 26/44 (59%) with RECIST SD were reclassified as PR by
Choi. Applying only RECIST led to a discreet underestimation of
prognosis, since the 24-month OS rate (landmark) was 91.8% (95%
CI, 83.3–100%) for Choi PR, somewhat higher than RECIST-
calculated SD. Nevertheless, the increase in the PR rate after
applying Choi criteria did not devalue the prognostic meaning of
response, which continued to exert an equivalent favourable
effect, as per both Choi and RECIST. Thus, the 24-month PFS
landmark for patients with Choi and RECIST PR was 40.4% (95% CI,
28.4–57.5%) and 48.0% (95% CI, 24.5–93.8%), respectively.
Individuals with PR according to Choi had better PFS and OS,
with HR 0.69 (95% CI, 0.29–1.61) and 0.86 (95% CI, 0.34–2.16),
respectively, versus those with SD, but the results were not
statistically significant.
Evaluation of tumour response in the first 3 months
Subsequently, the ‘earlier’ evaluation performed in 63 patients
after a median of 2.8 months (range, 1.1–4.4) was predictive of
PFS/OS (see Supplementary Table 3). In this scenario, PD by RECIST
was observed to have a more significant and greater effect on the
risk of death (HR for OS of 2.22, 95% CI, 1.13–4.25) compared to PD
defined by Choi criteria (HR for OS of 1.28, 95% CI, 0.58–2.83).
However, no statistical evidence was found that pointed toward
early evaluation by RECIST significantly predicted PFS
(Mantel–Byar test, p= 0.3), although we must bear in mind that,
by definition, this analysis only has two RECIST-defined categories
(PR and SD; the category PD by RECIST coincides with the
endpoint). Choi criteria evaluated at 3 months displayed a
significant association with PFS (Mantel–Byar test, p= 0.04), but
not OS (Supplementary Table 3).
Evaluation of tumour growth rate and attenuation variation rate
Finally, the relation between tumour size and AVR was examined,
as was the influence of these parameters on prognosis. First of all,
scatter plots were constructed that yield a graphic illustration of
the correlation between relative variations in HU and DVR (Δ sum
of diameters, %), at 6 and 3 months (Fig. 1c, d, respectively). These
scatter plots reveal that changes in attenuation are significantly
associated with variations in size, accounting for approximately
18% of their variation. In both cases, the slopes are moderate, as
these are slow-growing tumours. As expected, the DVR exhibited a
very high correlation with the TGR (Kendall’s τ= 0.960). Likewise,
the AVR explains 21% of the variability in tumour volume at
6 months.
To demonstrate how these changes projected on evaluations of
response, spider plots were drawn that illustrate the cross
relationship between: (1) DVR versus Choi criteria, and (2) AVR
versus RECIST (Supplementary Fig. 1A, B, respectively). In this case,
Table 1. Patients’ sociodemographic variables and baseline
characteristics
N= 85, %
Sex, male 49 (58%)
Age, median (range) 59 (21–84)
ECOG PS 0/1/2 35/49/1
Functioning tumour 21 (25%)
Sites of metastases
Liver 80 (94%)
Peritoneum 4 (5%)
Lymph nodes 26 (31%)
Lung 3 (4%)
Other 10 (12%)
Number of involved organs, median (range) 1 (0–4)
Ki67, median (range) 7 (1–20)
Prior SSA 55 (65%)
Previous lines excluding SSA
0 46 (54%)
1 20 (23%)
2 17 (20%)
3 2 (2%)
Sunitinib as first-line therapy 22 (26%)
Primary tumour surgery 33 (39%)
Locoregional therapies 4 (5%)
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given the slow growth rate, no significant changes in size were
observed between time point 0 and 3 or 6 months (Wilcoxon test,
p > 0.1). In contrast, attenuation did decrease significantly in both
spans (Wilcoxon test, p < 0.001). Figure 4 is a 3D-waterfall plot that
illustrates the relation between RECIST, AVR, and PFS in each
PanNET.
Next, we assessed whether changes in DVR, TGR and AVR could
predict prognosis during treatment with sunitinib. Supplementary
Table 4 shows the association between DVR, TGR and AVR with
survival endpoints at 3 and 6 months. While both parameters are
associated with PFS and OS in univariate analyses, only TGR is an
independent prognostic factor in the multivariate model for both
endpoints (see Supplementary Table 4).
DISCUSSION
Proper monitoring of response to antineoplastic treatments is
fundamental to reduce toxicity and costs. In the specific case of
sunitinib, this antiangiogenic drug induces biological changes in
the tumours, that are visible on CTs, such as variations in
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density,10,18 and produces a reduction in tumour size in most
cases, although these regressions rarely reach the threshold of PR
by RECIST.6 Choi criteria are based on subtle changes in
attenuation or size, theoretically making them a more adequate
method by which to track sunitinib’s effect in vivo (Smith et al.,
2010; Faivre et al., 2012; Raymond et al., 2018). Nonetheless, there
is scant experience with monitoring treatment effect using Choi
criteria in PanNETs treated with antiangiogenics.10,16,18
In other hypervascular tumours, such as hepatocellular carci-
noma, kidney cancer or gastrointestinal stromal tumours, Choi
criteria have been used to assess response to tyrosine-kinase
inhibitors having an antiangiogenic effect, such as sorafenib,
axitinib, sunitinib, pazopanib, etc.31 Other criteria have also been
developed to respond to the complexities specific to each
disease32,33 and treatment modality, such as the modified RECIST
in hepatocellular carcinoma treated with chemoembolisation or
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MASS (morphology, attenuation, size and structure) criteria in
renal cancer treated with antiangiogenics.34,35
In the CRIPNET_GETNE1504 study, we have observed that
assessment of response via RECIST v1.1 at 6 months categorises
more than half of the series as SD, with relatively few PR. In our
cohort, tumours with SD as per RECIST comprised a hetero-
geneous group from a prognostic perspective. This was pre-
sumably due to the fact that tumour growth was typically slow,
regardless of the efficacy of sunitinib. When tumours were
appraised by Choi criteria, the most noteworthy consequence
was the dramatic increase in PR rate (Δ+ 34.6%). All told, more
than half of the cases of RECIST SD were reclassified as PR by Choi.
The possibility of re-assessing sunitinib’s activity in PanNETs is
consistent with earlier information in the literature.10,16,18 Our data
point toward response as defined by Choi criteria, despite it being
more ‘permissive’, had a favourable effect on PFS/OS comparable
to RECIST-determined response. Since no evidence was found to
endorse a substantial decline in prognostic value, the conclusion is
that Choi was able to capture a clinically significant biological
effect that went unnoticed by RECIST. Therefore, most individuals
in PR as per Choi criteria in our series, in all likelihood actually
benefitted from the drug.
Although the percentage of subjects with RECIST SD reclassified
as PD was relatively low, had Choi criteria not been applied,
prognosis would have been overestimated in some 16%. However,
the impact of PD according to Choi criteria is complex and subtle.
On the one hand, Choi criteria employ a more restrictive threshold
of PD (10% versus 20% with RECIST). However, the definition
crucially excludes those tumours that, despite having grown, meet
the criterion of PR based on decreased attenuation. The overall
result was that, paradoxically, despite the slight increase in PD at
6 months with Choi criteria, PFS evaluated by these same criteria
was higher than RECIST PFS. The reason for this was that, while
there were more initial progressions with Choi criteria, the effect
was offset by tumours that maintained hypo-attenuation at
12 months, despite their slow growth. This latter observation is
in line with the data from the phase IV sunitinib trial.16 The
reduction of the cut-off (from 20 to 10%) improved the OS
prediction overall, but did not affect the specificity of the
definition of PD. Lamarca et al. recently published similar data.15
Therefore, the crux of the matter is what definition of PFS is the
most valid for use as a surrogate for OS in this setting. Imaoka
et al. previously considered that RECIST-defined PFS was an
acceptable OS surrogate in PanNETs.36 In contrast, our data reveal
that the correlation between PFS according to Choi and OS is
intermediate, and low, in the case of RECIST-based PFS. In line with
pre-set criteria, this is compatible with a lack of validity of the
latter surrogate.37 Nevertheless, correlation between surrogates
and patient-relevant endpoints alone should not be the sole
criterion to be contemplated in the case of indolent tumours, such
as neuroendocrine tumours, with several effective treatment
options after first-line. Be that as it may, Choi PFS displayed a
slightly better correlation with OS, although further studies are
needed to prove this surrogate’s validity.
Quite a different issue is whether the dichotomisation of response
entails loss of information, by ignoring gradualness.17 AVR and TGR
correctly predicted RECIST-based PFS. Said effect was already
present in studies at 3 months; hence, AVR and TGR can be early
markers of clinically significant activity of the drug. These
measurements of variation by unit of time worked better than
density- or size-related variations. Furthermore, both were non-
linearly interrelated; consequently, in multivariate analyses, only TGR
predicted survival endpoints. However, several nuances may limit
the practical use of TGR in some patients. First of all, the difficulty in
discerning the prognostic significance of slight differences in size
must be taken into account, especially since they are the ones that
occur in most patients. In addition, it cannot be ruled out that AVR
might modulate the effect of discrete growth, insofar as hypo-
attenuation translates into sustained antiangiogenic activity. None-
theless, the reader must be aware that this study is not statistically
powered to detect this kind of subgroup effect. It must also be
remembered that in patients not treated with antiangiogenics,
hypoattenuated PanNETs are generally associated with tumour de-
differentiation and poor prognosis.5
The CRIPNET_GETNE1504 study has certain limitations. Given the
low incidence of PanNETs, the sample size is relatively small. Despite
this, it is one of the largest series reported to date.10,16,18 Secondly,
the decision as to whether discontinue sunitinib or not was based
on each centre’s clinical practice, separate from the centralised
radiological criterion, which may have influenced the estimation of
PFS. The reader must likewise be aware that, while certain minimum
quality criteria were required, and 22 cases were excluded on the
basis of insufficient imaging quality, the studies were conducted in
accordance with the local protocols of each centre. Choi criteria
should be generalised by means of the rigorous application of
standardised protocols. This calls for prior consensus across the
radiodiagnostic and other departments involved in the manage-
ment of patients with neuroendocrine tumours. Finally, interobser-
ver agreement between the two radiologists who analysed response
was not examined. Nonetheless, earlier studies point toward the
level of concordance is generally high.38,39
In conclusion, in advanced PanNETs treated with sunitinib, RECIST
as the sole method of monitoring response entails an imprecise or
erroneous prognostic prediction in almost half of the patients.
RECIST PFS was a worse surrogate for OS than Choi-estimated PFS. In
contrast, Choi criteria capture the activity of sunitinib in a clinically
significant manner and suit the follow-up of slow-growing PanNETs.
If the data from this study are confirmed through data from clinical
trials, Choi criteria should be considered as standard for monitoring
advanced PanNETs response to antiangiogenic therapy.
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